Zeria Pharmaceutical Co Ltd
TSE:4559

Watchlist Manager
Zeria Pharmaceutical Co Ltd Logo
Zeria Pharmaceutical Co Ltd
TSE:4559
Watchlist
Price: 2 016 JPY -1.56%
Market Cap: ¥88.9B

Relative Value

The Relative Value of one Zeria Pharmaceutical Co Ltd stock under the Base Case scenario is hidden JPY. Compared to the current market price of 2 016 JPY, Zeria Pharmaceutical Co Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Zeria Pharmaceutical Co Ltd Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Zeria Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
JP
Zeria Pharmaceutical Co Ltd
TSE:4559
88.9B JPY 1 15.8 4.3 7.6
US
Eli Lilly and Co
NYSE:LLY
992.9B USD 16.5 53.4 35.9 38.4
US
Johnson & Johnson
NYSE:JNJ
541.8B USD 5.7 20.1 14.1 17.2
CH
Roche Holding AG
SIX:ROG
270B CHF 4.4 28.5 12.1 14.1
UK
AstraZeneca PLC
LSE:AZN
210.9B GBP 4.9 30.3 19.7 28.9
CH
Novartis AG
SIX:NOVN
218.4B CHF 4.9 19.3 15.4 19.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.4 16.4 11.4 13.3
US
Merck & Co Inc
NYSE:MRK
269.1B USD 4.2 14.1 10 11.9
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
151B USD 2.4 15.3 7.7 10.6
FR
Sanofi SA
PAR:SAN
94.9B EUR 1.4 6.9 6.3 6.3
P/E Multiple
Earnings Growth PEG
JP
Zeria Pharmaceutical Co Ltd
TSE:4559
Average P/E: 22
15.8
6%
2.6
US
Eli Lilly and Co
NYSE:LLY
53.4
54%
1
US
Johnson & Johnson
NYSE:JNJ
20.1
6%
3.4
CH
Roche Holding AG
SIX:ROG
28.5
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.3
38%
0.8
CH
Novartis AG
SIX:NOVN
19.3
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
16.4
2%
8.2
US
Merck & Co Inc
NYSE:MRK
14.1
14%
1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.3
27%
0.6
FR
Sanofi SA
PAR:SAN
6.9
25%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
JP
Zeria Pharmaceutical Co Ltd
TSE:4559
Average EV/EBITDA: 43.8
4.3
1%
4.3
US
Eli Lilly and Co
NYSE:LLY
35.9
34%
1.1
US
Johnson & Johnson
NYSE:JNJ
14.1
2%
7
CH
Roche Holding AG
SIX:ROG
12.1
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
19.7
10%
2
CH
Novartis AG
SIX:NOVN
15.4
6%
2.6
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
1%
11.4
US
Merck & Co Inc
NYSE:MRK
10
6%
1.7
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.7
0%
N/A
FR
Sanofi SA
PAR:SAN
6.3
8%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
JP
Zeria Pharmaceutical Co Ltd
TSE:4559
Average EV/EBIT: 93.9
7.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.4
37%
1
US
Johnson & Johnson
NYSE:JNJ
17.2
6%
2.9
CH
Roche Holding AG
SIX:ROG
14.1
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
28.9
23%
1.3
CH
Novartis AG
SIX:NOVN
19.9
12%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
0%
N/A
US
Merck & Co Inc
NYSE:MRK
11.9
8%
1.5
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.6
7%
1.5
FR
Sanofi SA
PAR:SAN
6.3
15%
0.4